Mutant KRAS G12V-specific TCR Transduced T Cell Therapy(Yingkai Saiwei)

N/A

Report date: 2023/12/25 17:24:09

Base Information

Drug NameMutant KRAS G12V-specific TCR Transduced T Cell Therapy(Yingkai Saiwei)
Drug Alias NameYK0901YK-0901
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsKRAS G12V inhibitors
TargetsKRAS G12V
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesYingkai Saiwei (Beijing) Biotechnology Co LtdPeking University
China Registration ClassN/A

Develop Information

Active CompaniesYingkai Saiwei (Beijing) Biotechnology Co LtdPeking University
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A